{
    "clinical_study": {
        "@rank": "40341", 
        "arm_group": [
            {
                "arm_group_label": "High dose, fasted", 
                "arm_group_type": "Experimental", 
                "description": "1 fixed dose combination (FDC) tablet vs 3 single tablets under fasted conditions"
            }, 
            {
                "arm_group_label": "High dose, fed", 
                "arm_group_type": "Experimental", 
                "description": "1 fixed dose combination (FDC) tablet vs 3 single tablets under fed conditions"
            }, 
            {
                "arm_group_label": "Low dose, fasted", 
                "arm_group_type": "Experimental", 
                "description": "2 fixed dose combination (FDC) tablets vs 4 single tablets under fasted conditions"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this trial is to demonstrate the relative bioavailability of 2 newly\n      developed fixed dose combinations (FDC) tablets containing empagliflozin & metformin XR and\n      the single tablets of empagliflozin and metformin XR when administered singularly"
        }, 
        "brief_title": "Relative Bioavailability of 2 Fixed Dose Combinations of Empagliflozin/Metformin Extended Release (XR) Compared With Single Tablets", 
        "completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Healthy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria:\n\n          1. Healthy males or females\n\n          2. Age 18-50 years (incl.)\n\n          3. Body Mass Index (BMI) 18.5 to 29.9 kg/m2 (incl.)\n\n          4. Subjects must be able to understand and comply with study requirements\n\n        Exclusion criteria:\n\n        Any deviation from healthy condition"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "50 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "72", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 4, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02106923", 
            "org_study_id": "1276.14"
        }, 
        "intervention": [
            {
                "arm_group_label": "High dose, fed", 
                "description": "Active Comparator: 1 x Empagliflozin/2x Metformin XR tablets", 
                "intervention_name": "1 tablet Empagliflozin/2 tablets Metformin XR", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "High dose, fasted", 
                "description": "Experimental: high dose Empagliflozin/Metformin XR, FDC tablet", 
                "intervention_name": "10 mg Empagliflozin/1000 mg Metformin XR", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Low dose, fasted", 
                "description": "Active Comparator: 1 x Empagliflozin/3 x Metformin XR tablets", 
                "intervention_name": "1 tablet 10 mg Empagliflozin/3 tablets Metformin XR", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Low dose, fasted", 
                "description": "Experimental:2 x low dose Empagliflozin/Metformin XR FDC tablets", 
                "intervention_name": "2 tablets 5 mg Empagliflozin/750 Metformin XR", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "High dose, fasted", 
                "description": "Active Comparator: 1 x Empagliflozin/2x Metformin XR tablets", 
                "intervention_name": "1 tablet Empagliflozin/2 tablets Metformin XR", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "High dose, fed", 
                "description": "Experimental: high dose Empagliflozin/Metformin XR, FDC tablet", 
                "intervention_name": "10 mg Empagliflozin/1000 mg Metformin XR", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Metformin"
        }, 
        "lastchanged_date": "May 19, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Austin", 
                    "country": "United States", 
                    "state": "Texas"
                }, 
                "name": "1276.14.1 Boehringer Ingelheim Investigational Site"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "Relative Bioavailability of Two Newly Developed FDC Tablet Strengths (10 mg/1000 mg and 5mg/750mg) of Empagliflozin/Metformin Extended Release Compared With the Free Combination of Empagliflozin and Metformin Extended Release in Healthy Subjects (an Open-label, Randomised, Single Dose, Two-way Crossover Study)", 
        "overall_contact": {
            "email": "clintriage.rdg@boehringer-ingelheim.com", 
            "last_name": "Boehringer Ingelheim Call Center", 
            "phone": "1-800-243-0127"
        }, 
        "overall_official": {
            "affiliation": "Boehringer Ingelheim", 
            "last_name": "Boehringer Ingelheim", 
            "role": "Study Chair"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "AUC0-tz (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point), for empagliflozin and metformin", 
                "safety_issue": "No", 
                "time_frame": "up to 72 hours after administration"
            }, 
            {
                "measure": "Cmax (maximum measured concentration of the analyte in plasma, for empagliflozin and metformin", 
                "safety_issue": "No", 
                "time_frame": "up to 72 hours after administration"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02106923"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "AUC0-infinity (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity), for empagliflozin and metformin", 
            "safety_issue": "No", 
            "time_frame": "up to 72 hours after administration"
        }, 
        "source": "Boehringer Ingelheim", 
        "sponsors": {
            "collaborator": {
                "agency": "Eli Lilly and Company", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Boehringer Ingelheim", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}